Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. / Helleberg, Marie; Niemann, Carsten Utoft; Moestrup, Kasper Sommerlund; Kirk, Ole; Lebech, Anne Mette; Lane, Clifford; Lundgren, Jens.

I: Journal of Infectious Diseases, Bind 222, Nr. 7, 2020, s. 1103-1107.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Helleberg, M, Niemann, CU, Moestrup, KS, Kirk, O, Lebech, AM, Lane, C & Lundgren, J 2020, 'Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy', Journal of Infectious Diseases, bind 222, nr. 7, s. 1103-1107. https://doi.org/10.1093/infdis/jiaa446

APA

Helleberg, M., Niemann, C. U., Moestrup, K. S., Kirk, O., Lebech, A. M., Lane, C., & Lundgren, J. (2020). Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. Journal of Infectious Diseases, 222(7), 1103-1107. https://doi.org/10.1093/infdis/jiaa446

Vancouver

Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C o.a. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. Journal of Infectious Diseases. 2020;222(7):1103-1107. https://doi.org/10.1093/infdis/jiaa446

Author

Helleberg, Marie ; Niemann, Carsten Utoft ; Moestrup, Kasper Sommerlund ; Kirk, Ole ; Lebech, Anne Mette ; Lane, Clifford ; Lundgren, Jens. / Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. I: Journal of Infectious Diseases. 2020 ; Bind 222, Nr. 7. s. 1103-1107.

Bibtex

@article{0cf5f519b01c48e9b2100cb42c51e439,
title = "Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy",
abstract = "The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.",
keywords = "Case report, COVID-19, Immunocompromised, Remdesivir, SARS-CoV-2",
author = "Marie Helleberg and Niemann, {Carsten Utoft} and Moestrup, {Kasper Sommerlund} and Ole Kirk and Lebech, {Anne Mette} and Clifford Lane and Jens Lundgren",
year = "2020",
doi = "10.1093/infdis/jiaa446",
language = "English",
volume = "222",
pages = "1103--1107",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "7",

}

RIS

TY - JOUR

T1 - Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy

AU - Helleberg, Marie

AU - Niemann, Carsten Utoft

AU - Moestrup, Kasper Sommerlund

AU - Kirk, Ole

AU - Lebech, Anne Mette

AU - Lane, Clifford

AU - Lundgren, Jens

PY - 2020

Y1 - 2020

N2 - The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.

AB - The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.

KW - Case report

KW - COVID-19

KW - Immunocompromised

KW - Remdesivir

KW - SARS-CoV-2

U2 - 10.1093/infdis/jiaa446

DO - 10.1093/infdis/jiaa446

M3 - Journal article

C2 - 32702095

AN - SCOPUS:85090177512

VL - 222

SP - 1103

EP - 1107

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 7

ER -

ID: 258330405